top of page

ASCO 2025: France based Transgene presented data for its personalized cancer vaccine in the adjuvant setting for HPV- head and neck cancer

  • blonca9
  • Jun 2
  • 1 min read

Updated: 9 hours ago

Chairman and CEO Alessandro Riva describes the computational work that is done to choose the personalized neoantigens for this cancer vaccine, and he describes why head and neck was a good fit to test the therapy out in. Plus, he covers the data and talks about next steps.



In the interview, the number of patients randomized in the trial is misstated. The correct numbers are 17 patients in the TG4050 vaccine arm and 16 patients in the observational arm, as presented at ASCO 2025.


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTVHQ

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Genezen_Logo_RGB.png

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page